Aethlon (AEMD) has disclosed a new risk, in the Accounting & Financial Operations category.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Aethlon faces a multitude of risks that could significantly impact its financial stability and future operations. The company has a history of substantial losses and anticipates continued financial challenges, necessitating additional financing that may dilute current stockholder ownership. Furthermore, Aethlon’s limited experience with large-scale contracts and reliance on third-party suppliers for critical materials could disrupt the production of its Hemopurifier, while regulatory compliance issues and potential obsolescence of its technology pose further threats. The company also faces the risk of delisting from the Nasdaq Capital Market, which could adversely affect its financial condition and complicate the sale of shares, alongside challenges in attracting and retaining key executive personnel amid its planned operational expansion.
The average AEMD stock price target is $1.50, implying 28.21% upside potential.
To learn more about Aethlon’s risk factors, click here.